Abstract
To summarize the experience in intraarterial neoadjuvant chemotherapy for extremity osteosarcoma. Between January 2002 and December 2007,111 patients with stage IIB extremity osteosarcoma received preoperative intraarterial therapy with subcutaneous implantation of chemotherapy pump as well as en bloc resection, and postoperative adjuvant chemotherapy. There were 63 males and 48 females with an average age of 18 (range, 14 ~ 39 years). The time from symptom onset to hospitalization varied from several days to 6 months. The induction chemotherapy regimen includes: epirubicin [50 ~ 70 mg/m2 by 4-hour intraarterial infusion/day for 3 day] and cisplatin [100 ~ 120 mg/m2 by 2-hour intraarterial infusion/day for 3 days] repetitively every 2 ~ 3 weeks. Among which 24 cases only received two cycles induction chemotherapy was set to nonstandard chemotherapy group and 87 cases received three to six cycles induction chemotherapy set to standard chemotherapy group. The number of preoperative chemotherapy-cycles of standard chemotherapy group depends on the clinical and radiographic evaluation of chemotherapy efficacy. Median follow-up time was 28(8 ~ 48) months. The rate of limb preservation surgery was 89.53% (77/86) in standard chemotherapy group,and was 37.5% (9/24) in nonstandard chemotherapy group. Kaplan-Meier survival analysis showed that the 3-year overall survival rate and disease free survival rate of all the 111 cases were 68.3% and 65.9% respectively. There were significant differences in overall survival rate (38.9%, 80.0%, P = 0.000), disease free survival rate (30.1%, 79.5%, P = 0.000), distant metastasis rate (66.67%, 16.09%, P = 0.0000) and local recurrence rate (58.33%, 13.79%, P = 0.0000) between nonstandard chemotherapy group and standard chemotherapy group. Standard intraarterial neo-adjuvant chemotherapy was more effective than nonstandard intraarterial induction chemotherapy to stage IIB extremity osteosarcoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rosen G, Marcove RC, Caparros B et al (1979) Primary osteogenic sarcoma - the rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163–2192
Bacci G, Longhi A, Versari M et al (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Fifteen year experience in 789 patients treated at a single institution. Cancer 106:1154–1161
Guo W, Yang RL, Tang XD et al (2004) Neoadjuvant chemotherapy for osteosarcoma. Natl Med J Chin 84:1186–1190
Ferrari S, Smeland S, Mercuri M, Italian and Scandinavian Sarcoma Groups et al (2005) Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, Cisplatin, and doxorubicin for patients with localized ostesarcoma of the extremity. A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23:8845–8852
Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574–1580
Bacci G, Ferrari S, Longhi A et al (2003) Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol 21:4662–4663
Li D, Cui Q, Fan H et al (2005) Extendible replacement of the distal femur in the treatment of osteosarcoma in growing individuals. Chin J Reparative Reconstr Surg 19:560–562
Dahlin DC, Coventry MB (1967) Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am 49:101–110
Lin F, Dong Y, Tang X et al (2006) Clinical analysis on efficacy and prognosis of new adjuvant chemotherapy for stageIIB osteosarcoma. Tumor 26:1011–1014
Rao BN, Rodriguez-Galindo C (2003) Intra-arterial cisplatin in osteosarcoma: same question, different answer. Ann Surg Oncol 10:481–483
Guo wei; Li dasen; Shen danhua et al (2006) Treatment of multifocal osteosarcoma. Chin J Orthop 26:378–380
Bramwell VH, Burgers MV, Souhami RL et al (1997) A randomized comparison of two short intensive chemotherapy regimens in children and young adults with osteosarcoma: results in patients with metastases: a study of the European Osteosarcoma Intergroup. Sarcoma 1:155–160
Souhami RL, Craft AW, Van der Eijken JW et al (1997) Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 350(9082):911–917
Stewart DJ, Benjamin RS, Zimmerman S et al (1983) Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II). Cancer Res 43:917–920
Jaffe N, Knapp J, Chuang VP et al (1983) Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer 51:402–407
Wilkins RM, Cullen JW, Camozzi AB et al (2005) Improved survival in primary nonmetastatic pediatric osteosarcoma of the extremity. Clin Orthop Relat Res 438:128–136
Hugate RR, Wilkins RM, Kelly CM et al (2008) Intraarterial chemotherapy for extremity osteosarcoma and MFH in adults. Clin Orthop Relat Res 466:1292–1301
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, D., Cui, Q., Liu, Y. et al. Chemotherapy Response Analysis for Osteosarcom with Intra-arterial Chemotherapy by Subcutaneous Implantable Delivery System. Pathol. Oncol. Res. 17, 947–953 (2011). https://doi.org/10.1007/s12253-011-9408-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12253-011-9408-5